Skip to content
Disclosery

Propel Bio Management, LLC

Follow

13F filer, CIK 1969764, Los Angeles, CA

Propel Bio Management, LLC reported $99,894,525 across 16 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12. Its ten largest share positions make up 87.06% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000898432-25-000886

Period
2025-09-30
Reported value
$99.9M
Holdings
16
Top 10 weight
87.06%
New
6
Sold out
6

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MISTadded+3,333,333$6.67M
CLDXnew+155,000$4.01M
CMPSnew+510,000$2.92M
NKTRnew+49,000$2.79M
JSPRnew+1,028,806$2.45M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ACHVreduced-2,366,666-$7.45M
PHATreduced-370,000-$4.35M
CAPRexited-70,000-$695K
MAAT PHARMA SACAexited-94,181-$452K
ATHIRA PHARMA INCexited-1,492,792-$451K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0000898432-25-000886, largest first. % of portfolio is the value over $99,894,525, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PAGPPLAINS GP HLDGS L PQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,272,360 shares; 2024Q4: 1,272,360 shares; 2025Q1: 1,272,360 shares; 2025Q2: 1,272,360 shares; 2025Q3: 1,272,360 shares 1,272,360$23.2M23.23%0Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,453,092 shares; 2024Q4: 2,453,092 shares; 2025Q1: 2,453,092 shares; 2025Q2: 6,153,091 shares; 2025Q3: 3,786,425 shares 3,786,425$11.9M11.94%-2,366,666Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 343,729 shares; 2024Q4: 343,729 shares; 2025Q1: 228,884 shares; 2025Q2: 228,884 shares; 2025Q3: 228,884 shares 228,884$10.9M10.88%0Timeline
MISTMILESTONE PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,451,557 shares; 2025Q2: 1,791,557 shares; 2025Q3: 5,124,890 shares 5,124,890$10.2M10.26%+3,333,333Timeline
Applied Therapeutics IncApplied Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,567,858 shares; 2024Q4: 9,615,420 shares; 2025Q1: 11,285,420 shares; 2025Q2: 11,285,420 shares; 2025Q3: 11,285,420 shares 11,285,420$6.83M6.83%0
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 869,927 shares; 2024Q4: 989,927 shares; 2025Q1: 1,134,927 shares; 2025Q2: 922,927 shares; 2025Q3: 552,927 shares 552,927$6.51M6.51%-370,000Timeline
ABEOABEONA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 624,022 shares; 2024Q4: 624,022 shares; 2025Q1: 624,022 shares; 2025Q2: 974,022 shares; 2025Q3: 974,022 shares 974,022$5.14M5.15%0Timeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 17,000 shares; 2025Q1: 177,600 shares; 2025Q2: 226,052 shares; 2025Q3: 438,509 shares 438,509$4.71M4.72%+212,457Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,000 shares 155,000$4.01M4.01%newTimeline
TCRXTSCAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,087,139 shares; 2024Q4: 2,087,139 shares; 2025Q1: 2,087,139 shares; 2025Q2: 2,087,139 shares; 2025Q3: 1,932,304 shares 1,932,304$3.52M3.52%-154,835Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 80,000 shares; 2024Q4: 25,209 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 510,000 shares 510,000$2.92M2.93%newTimeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 49,000 shares 49,000$2.79M2.79%newTimeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 20,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,028,806 shares 1,028,806$2.45M2.45%newTimeline
ZVRAZEVRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 179,874 shares; 2024Q4: 179,874 shares; 2025Q1: 179,874 shares; 2025Q2: 231,874 shares; 2025Q3: 231,874 shares 231,874$2.21M2.21%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 90,000 shares 90,000$1.94M1.94%newTimeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 149,279 shares 149,279$618K0.62%newTimeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CAPRCAPRICOR THERAPEUTICS INC70,000$695Kshares
MAAT PHARMA SACAMAAT PHARMA SACA94,181$452Kshares
ATHIRA PHARMA INCATHIRA PHARMA INC1,492,792$451Kshares
EIGRQEIGER BIOPHARMACEUTICALS146,381$423Kshares
WTS - Achieve Life SciWTS - Achieve Life Sci3,699,999$13.7Kshares
CHINOOK THERAPEUTICS CVRCHINOOK THERAPEUTICS CVR79,357$2.5Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000898432-25-000886 base2025-11-12acceptance time not in the bulk data set